Related references
Note: Only part of the references are listed.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
Gavin Giovannoni et al.
EUROPEAN JOURNAL OF NEUROLOGY (2022)
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
Helmut Butzkueven et al.
EUROPEAN JOURNAL OF NEUROLOGY (2022)
Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies
Bruce A. C. Cree et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions
T. Derfuss et al.
CLINICAL NEUROPHYSIOLOGY (2020)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Ludwig Kappos et al.
JAMA NEUROLOGY (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
Huah Shin Ng et al.
EXPERT OPINION ON DRUG SAFETY (2020)
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky et al.
LANCET NEUROLOGY (2020)
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
Benjamin Turner et al.
JOURNAL OF NEUROLOGY (2019)
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Dalia Rotstein et al.
NATURE REVIEWS NEUROLOGY (2019)
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies
Lori Mayer et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis
Rachael McCool et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
Colm Elliott et al.
BRAIN (2019)
P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
S.L. Hauser et al.
CLINICAL NEUROPHYSIOLOGY (2019)
P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
J.S. Wolinsky et al.
CLINICAL NEUROPHYSIOLOGY (2019)
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Frederik Barkhof et al.
NEUROLOGY (2019)
Multiple sclerosis - a review
R. Dobson et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis
J. S. Wolinsky et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)
Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
G. Giovannoni et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)
Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
Bernard M. J. Uitdehaag
CNS DRUGS (2018)
EFFECT OF OCRELIZUMAB ON UPPER LIMB FUNCTION IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN THE ORATORIO STUDY (ENCORE)
Edward Fox et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2018)
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Ivan Jelcic et al.
CELL (2018)
Ocrelizumab: A Review in Multiple Sclerosis
Yahiya Y. Syed
CNS DRUGS (2018)
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Edward J. Fox et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
AN EXPLORATORY ANALYSIS OF EFFICACY OF OCRELIZUMAB FOR MULTIPLE SCLEROSIS PATIENTS WITH INCREASED DISABILITY
Y. Xu et al.
VALUE IN HEALTH (2018)
Long-term Reduction of Relapse Rate and Confirmed Disability progression after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
S.L. Hauser et al.
Multiple Sclerosis and Related Disorders (2018)
Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
D.L. Arnold et al.
Multiple Sclerosis and Related Disorders (2018)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
Per Soelberg Sorensen et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2016)
Epidemiology of Multiple Sclerosis
Jonathan Howard et al.
NEUROLOGIC CLINICS (2016)
EDSS STATE AND HEALTH UTILITY MEASURED BY EQ5D IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
M. Daigl et al.
VALUE IN HEALTH (2016)
Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy
Rui Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Arumugam Palanichamy et al.
JOURNAL OF IMMUNOLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis
Ranjan Dutta et al.
PROGRESS IN NEUROBIOLOGY (2011)
The changing demographic pattern of multiple sclerosis epidemiology
Nils Koch-Henriksen et al.
LANCET NEUROLOGY (2010)
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis
Suhayl Dhib-Jalbut
NEUROLOGY (2007)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
